-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, Chia Tai Tianqing officially announced that the company and Anyuan Pharma have reached a strategic cooperation on the rights development and commercialization of AP025 and AP026 in China and some Asian regions.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
AP025 is a fusion protein of human FGF21, and it is the first drug with the same target in China to enter the clinic
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
Chia Tai Tianqing said that compared with other similar target drugs in the world, AP025 uses pure natural human FGF21 as the active form, which reduces the possible immunogenicity
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
Domestic clinical development of AP025
Source: Minet China Drug Clinical Trials Publicity Library
AP026 is a FGF21/GLP-1 bifunctional protein.
At present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
At present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
Sales of terminal GLP-1 receptor agonists in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, there are 8 GLP-1 receptor agonists on the market in China, of which the only domestic marketed drugs are Hansoh's polyethylene glycol loxenatide and Renhui's benaglutide
.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
Source: Enterprise Announcement, Mi Intranet Database
On April 25, Chia Tai Tianqing officially announced that the company and Anyuan Pharma have reached a strategic cooperation on the rights development and commercialization of AP025 and AP026 in China and some Asian regions.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
AP025 is a fusion protein of human FGF21, and it is the first drug with the same target in China to enter the clinic
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
Chia Tai Tianqing said that compared with other similar target drugs in the world, AP025 uses pure natural human FGF21 as the active form, which reduces the possible immunogenicity
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
Domestic clinical development of AP025
Source: Minet China Drug Clinical Trials Publicity Library
AP026 is a FGF21/GLP-1 bifunctional protein.
At present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
At present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
Sales of terminal GLP-1 receptor agonists in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, there are 8 GLP-1 receptor agonists on the market in China, of which the only domestic marketed drugs are Hansoh's polyethylene glycol loxenatide and Renhui's benaglutide
.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
Source: Enterprise Announcement, Mi Intranet Database
On April 25, Chia Tai Tianqing officially announced that the company and Anyuan Pharma have reached a strategic cooperation on the rights development and commercialization of AP025 and AP026 in China and some Asian regions.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
Anyuan Pharma will receive a down payment of up to 342 million yuan and Milestone payments, and single-digit tiered royalties on net sales
.
The two innovative drugs under this cooperation are used to treat patients with NASH (non-alcoholic steatohepatitis) and T2DM (type II diabetes), both of which belong to digestive system and metabolic drugs.
The market size of medical institutions exceeds 100 billion yuan
.
AP025 is a fusion protein of human FGF21, and it is the first drug with the same target in China to enter the clinic
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
.
In the field of NASH, only India's Zydus Cadila's PPARα/γ dual agonist has been approved in the world
.
In the past, NASH drugs such as Gilead's selonsertib (ASK1 inhibitor), Intercept's obeticholic acid, and Genfit's Elafibranor (PPARα and δ dual agonist), which were favored by the industry in the past, have problems in terms of safety and comprehensive efficacy, and have been listed in the market one after another.
Front halberd
.
Up to now, the global NASH drug market is still in a situation of tens of thousands of horses
.
Chia Tai Tianqing said that compared with other similar target drugs in the world, AP025 uses pure natural human FGF21 as the active form, which reduces the possible immunogenicity
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
.
The molecule's potent reduction in liver fat was observed in preclinical experiments
.
At the same time, the drug's good safety and long half-life have been observed in Phase I clinical trials
.
Domestic clinical development of AP025
Source: Minet China Drug Clinical Trials Publicity Library
AP026 is a FGF21/GLP-1 bifunctional protein.
At present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
enterprise enterprise enterpriseAt present, the drug has launched Phase I clinical trials abroad, and plans to apply for IND in China this year
.
In recent years, GLP-1 RA has gradually gained its status in major guidelines because of its significant hypoglycemic effect and multiple benefits
.
In the field of global GLP-1 receptor agonists, Eli Lilly and Novo Nordisk 's products occupy the top sales in the market
.
According to the company's annual report, the global sales of Lilly's dulaglutide and Novo Nordisk's semaglutide in 2021 will be US$6.
472 billion respectively (about 42.
495 billion yuan at the exchange rate on April 25, the same below) , 6.
128 billion US dollars (about 40.
235 billion yuan)
.
Sales of terminal GLP-1 receptor agonists in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, there are 8 GLP-1 receptor agonists on the market in China, of which the only domestic marketed drugs are Hansoh's polyethylene glycol loxenatide and Renhui's benaglutide
.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
hospital hospital hospital.
According to data from Minet.
com, in 2020, the sales of terminal GLP-1 receptor agonists in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan, a year-on-year increase of 42.
45%.
In the first half of 2021, the sales growth rate exceeded 80%.
Among them, Novo Nordisk's liraglutide injection and Lilly's dulaglutide injection accounted for more than 90% of the domestic market share
.
In the future, with the entry of more domestic drugs, Novo Nordisk's import monopoly will change
.
Source: Enterprise Announcement, Mi Intranet Database
Source: Enterprise Announcement, Mi Intranet Database 
